URL has been copied successfully!
bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Tuesday morning.
The move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath Lung to the diagnostic pathway.
Clinical Case Study Success
The company released data regarding a 71-year-old former smoker with multiple pulmonary nodules. Traditionally, such cases lead to invasive biopsies. However, the CyPath Lung test returned a result of “Unlikely Malignancy.”
A follow-up scan in October confirmed the nodules were benign.
Enhancing Diagnostic Clarity
“Multiple small nodules in a high-risk patient pose a diagnostic challenge,” said Daya Nadarajah, MD, the patient’s pulmonologist.
He noted the negative result provided comfort …
Please follow us:
This post was originally published here
